PET in neuroscience: Dopaminergic, GABA/benzodiazepine, and opiate system;PET in den neurowissenschaften: Dopaminerges, GABA/benzodiazepin- und opiatsystem

NuklearMedizin

Volumn 43, Issue 1, 2004, Pages 33-42

  Bartenstein, P ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Dopaminergic system; GABA benzodiazepine system; Opiate system; PET

Indexed keywords

4 AMINOBUTYRIC ACID; BENZODIAZEPINE; OPIATE; RADIOPHARMACEUTICAL AGENT; TRACER;

DOPAMINERGIC SYSTEM; GABAERGIC SYSTEM; NEUROSCIENCE; NEUROTRANSMISSION; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 1242307947     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1623912     Document Type: Review

References (121)

1. Abi-Dargham A, Krystal JH, Anjilvel S et al. Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and I-123 iomazenil. Am J Psychiatry 1998; 155: 1550-5.
2. Albertson TE, Joy RM, Stark LG. Modification of kindled amygdaloid seizures by opiate agonists and antagonists. J Pharmakol Exp Ther 1984; 228: 620-7.
3. Albin RL, Reiner A, Anderson KD et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol. 1992; 31: 425-30.
4. Antonini A, Leenders KL, Vontobel P et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997; 120: 2187-95.
5. Arnold S, Berthele A, Drzezga A et al. Reduction of benzodiazepine receptor binding is related to the seizure onset zone in extratemporal focal cortical dysplasia. Epilepsia 2000; 41: 818-24.
6. Atack JR, Smith AJ, Emms F et al. Regional differences in the inhibition of mouse in vivo (3H)Ro 15-1788 binding reflect selectivity for alpha 1 versus alpha 2 and alpha 3 subunit-containing GABAA receptors. Neuropsychopharmacology 1999; 20: 255-62.
7. Banati RB, Newcombe J, Gunn RN et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000; 123: 2321-37.
8. Barker RA, Dunnett SB. Functional integration of neural grafts in Parkinson's disease. Nat Neurosci 1999; 2: 1047-8.
9. Bartenstein P, Ludolph A, Schober O et al. Benzodiazepine receptors and cerebral blood flow in partial epilepsy. Eur J Nucl Med 1991; 18: 111-8.
10. Bartenstein PA, Duncan JS, Prevett MC et al. Investigation of the opioid system in absence seizures with positron emission tomography. J Neurol Neurosurg Psychiatry. 1993; 56: 1295-302.
11. Bartenstein PA, Prevett MC, Duncan JS et al. Quantification of opiate receptors in two patients with mesiobasal temporal lobe epilepsy, before and after selective amygdalohippocampectomy, using positron emission tomography. Epilepsy Res 1994; 18: 119-25.
12. Bartenstein P, Grünwald F, Kuwert T et al. Klinische Anwendungen der Single-Photon-Emissionstomographie in der Neuromedizin. 1: Neuroonkologie, Epilepsien, Basalganglien-erkrankungen, zerebrovaskuläre Erkrankungen. Nuklearmedizin 2000; 39: 180-95.
13. 18F)CPFPX and PET. Neuroimage. 2003; 19: 1760-9
14. Beer HF, Bläuenstein PA, Hasler PH et al. In vitro and in vivo evaluation of Iodine-123-Ro 16-0154: A new imaging agent for SPECT investigations of benzodiazepine receptors. J Nucl Med 1990; 31: 1007-14.
15. 11C)-carfentanil and positron emission tomography (PET). Pain. 2002; 99: 589-98.
16. Bigliani V, Pilowsky LS. In vivo neuropharmacology of schizophrenia. Br J Psychiatry (Suppl) 1999; 38: 23-33.
17. Breier A, Su TP, Saunders R et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A. 1997; 94: 2569-74.
18. Brooks DJ, Ibanez V, Sawle GV et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28: 547-55.
19. Brooks DJ. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol 2000; 247 (Suppl 2): II 11-8.
20. Cagnin A, Brooks DJ, Kennedy AM et al. In-vivo measurement of activated microglia in dementia. Lancet 2001; 358 (9280): 461-7.
21. Calautti C, Baron JC. Functional neuroimaging studies of motor recovery after stroke in adults: a review. Stroke 2003; 34: 1553-66.
22. 18F-FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635. Nucl Med Biol 2000; 27: 493-7.
23. Carter BD, Medzihradsky F. Receptor mechanisms of opioid tolerance in SH-SY5Y human neural cells. Mol Pharmacol 1993; 43: 465-73.
24. Chavkin C, Shoemaker WJ, McGinty JF et al. Characterization of the prodynorphin and proenkephalin neuropeptide systems in rat hippocampus. J Neurosci. 1985; 5: 808-16.
25. 18F)-fluoroethyl)-piperone: a novel ligand for cerebral dopamine receptor studies with PET. Life Sci 1987; 40: 81-8.
26. Cohen RM, Andreason PJ, Doudet DJ et al. Opiate receptor avidity and cerebral blood flow in Alzheimer's disease. J Neurol Sci. 1997; 148: 171-80.
27. 11C-flunitrazepam displacement in the brain of the life baboon. Nature 1979; 280: 329-31.
28. Cunningham V, Jones T. Spectral analysis of dynamic PET data. J Cereb Blood Flow Metab 1993; 13: 15-23.
29. 11C)Carfentanil. Int J Appl Radiat Isot 1985; 36: 303-6.
30. DeLorey TM, Olsen RW. γ-Aminobutyric acid-A receptor structure and function. J Biol Chem 1992; 267: 16747-50.
31. Fahey FH. Positron emission tomography instrumentation. Radiol Clin North Am 2001; 39: 919-29.
32. Forutan F, Estalji S, Beu M et al. Distribution of 5HT2A receptors in the human brain: comparison of data in vivo and post mortem. Nuklearmedizin 2002: 197-201.
33. Foster NL, Minoshima S, Johanns J et al. PET measures of benzodiazepine receptors in progressive supranuclear palsy. Neurology 2000; 54: 1768-73.
34. Fowler JS, Volkow ND, Wang GJ et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996; 379: 733-6.
35. Frenk H. Pro- and anticonvulsant actions of morphine and the endogenous opioids: involvement and interactions of multiple opiate and non-opiate systems. Brain Res Rev 1983; 6: 197-210.
36. 11C-suriclone by positron emission tomography. Eur J Pharmacol 1986; 122: 381-3.
37. Frost JJ, Mayberg HS, Fisher RS et al. Mü-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy. Ann Neurol 1988; 23: 231-7.
38. 11C)-carfentanil binding to opiate receptors in humans measured by positron emission tomography. J Cereb Blood Flow Metab 1989; 9: 398-409.
39. 18F)Fluoro-dopa, an analogue of dopa, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine. Proc Natl Acad Sci USA 1978; 75: 464-7.
40. 11C)PK11195 and positron emission tomography in patients after ischemic stroke. Neuroreport 2000; 11: 2957-60.
41. Gründer G, Siessmeier T, Lange-Asschenfeldt C et al. PET imaging of benzodiazepine receptors in the human brain with F-18 fluoroethylflumazenil. Eur J Nucl Med 2001; 28: 1463-70.
42. 18F-desmethoxyfallypride. J Nucl Med. 2003; 44: 109-16.
43. Halldin C, Gulyas B, Langer O et al. Brain radioligands - state of the art and new trends. Q J Nucl Med. 2001; 45: 139-52.
44. Hammers A, Koepp MJ, Richardson MP et al. Central benzodiazepine receptors in malformations of cortical development: A quantitative study. Brain 2001; 124: 1555-65.
45. 11C)-flumazenil PET in mesial temporal lobe epilepsy. Neurology 2001; 56: 897-906.
46. Heinz A, Reimold M, Hermann D et al. Craving and relapse are associated with μ-opioid availability in alcoholics a C-11 carfentanil study J Nucl Med 2001; 42 (suppl): 107.
47. Heiss WD, Würker M. Möglichkeiten und Grenzen funktioneller bildgebender Verfahren beim Parkinson-Syndrom. Nervenarzt 1999; 70 (suppl 1): S 2-10.
48. 2O positron emission tomography predicts irreversible ischemic cortical damage in stroke patients receiving acute thrombolytic therapy. Stroke 2000; 31: 366-9.
49. Henry TR, Frey KA, Sackellares JC et al. In vivo cerebral metabolism and central benzodiazepine-receptor binding in temporal lobe epilepsy. Neurology 1993; 43: 1998-2006.
50. Jacobs AH, Li H, Winkeler A et al. PET-based molecular imaging in neuroscience. Eur J Nucl Med Mol Imaging 2003; 30: 1051-65.
51. Jalan R, Turjanski N, Taylor Robinson SD et al. Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis. Gut. 2000; 46: 546-52.
52. 18F-2-oxoquazepam. J Label Compound Radiopharm 1988; 26: 334-5.
53. 11C)diprenorphine in normal volunteers. J Neurosci Methods. 1988; 23: 121-9.
54. Jones AK, Liyi Q, Cunningham VV et al. Endogenous opiate response to pain in rheumatoid arthritis and cortical and subcortical response to pain in normal volunteers using positron emission tomography. Int J Clin Pharmacol Res. 1991; 11: 261-6.
55. 11C) diprenorphine and positron emission tomography. J Cereb Blood Flow Metab. 1999; 19: 803-8.
56. Juhasz C, Chugani DC, Muzik O et al. Relationship of flumazenil and glucose PET abnormalities to neocortical epilepsy surgery outcome. Neurology 2001; 56: 1650-8.
57. Kelsley JE, Belluzi JD. Endorphin mediation of post-ictal effects of kindled seizures in rats. Brain Res 1982; 253: 337-40.
58. 18F cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 2000; 295: 1070-6.
59. Koepp MJ, Gunn RN, Lawrence AD et al. Evidence for striatal dopamine release during a video game. Nature 1998; 393: 266-8.
60. Koepp MJ, Richardson MP, Brooks DJ et al. Focal cortical release of endogenous opioids during reading-induced seizures. Lancet 1998; 352: 952-5.
61. 11C-flumazenil PET in patients with refractory temporal lobe epilepsy and normal MRI. Neurology 2000; 54: 332-9.
62. Koepp MJ, Duncan JS. PET: Opiate receptor mapping. In: Henry TR, Duncan JS, Berkovic SF (eds). Functional imaging in the epilepsies. Philadelphia: Lippincott Williams & Wilkins 2000: 145-56.
63. 11C) flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 991; 11: 735-44.
64. 18FDG PET: neurophysiological and metabolic implications. J Neurol Neurosurg Psychiatry 1998; 65: 170-6.
65. Kuwert T, Bartenstein P, Grünwald F et al. Klinische Wertigkeit der Positronenemissionstomographie in der Neuromedizin: Positionspapier zu den Ergebnissen einer interdisziplinären Konsensuskonferenz. Nervenarzt 1998; 69: 1045-60.
66. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4: 153-8.
67. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000; 20: 423-51.
68. 11C-flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab 1995; 15: 152-65.
69. Lever JR, Ilgin N, Musachio JL et al. Autoradiographic and SPECT imaging of cerebral opioid receptors with an iodine-123 labeled analogue of diprenorphine. Synapse 1998; 29: 172-82.
70. 11C flumazenil. Brain 2000; 123: 2289-96.
71. Lochmann M, Buchholz HG, Siesmeier T et al. Comparison of different quantification methods for calculating binding potential (BP) of the new unselective opiate-receptor ligand F-18 fluoroethyldiprenorphine. J Cereb Blood Flow Metab 2003, 23 (suppl 1): 669.
72. 11C-methyl)-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990; 10: 740-7.
73. Macdonald GA, Frey KA, Agranoff BW et al. Cerebral benzodiazepine receptor binding in vivo in patients with recurrent hepathic encephalopathy. Hepatology 1997; 26: 277-82.
74. Madar I, Lesser RP, Krauss G et al. Imaging of delta- and mu-opioid receptors in temporal lobe epilepsy by positron emission tomography. Ann Neurol 1997; 41: 358-67.
75. Malizia AL, Cunningham VJ, Bell CJ et al. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET-study. Arch Gen Psychiatry 1998; 55: 715-20.
76. Mayberg HS, Sadzot B, Meltzer CC et al. Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography. Ann Neurol 1991; 30: 3-11.
77. 11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. Int J Appl Radiat Isot 1984; 35: 973-6.
78. 18F)fluoro-L-dopa and (3H)L-dopa in rats. Biochem Pharmacol 1990 15; 39: 1853-60.
79. 18F]fluoroethyl)flumazenil to central benzodiazepine receptors measured in living baboon by positron emission tomography. Eur J Pharmacol 1992; 218: 109-15.
80. 18F-fallypride. Nucl Med Biol 1999; 26: 519-27.
81. Munz F, Ludwig T, Ziegler S et al. Performance assessment of parallel spectral analysis: Towards a practical performance model for parallel medical applications. Proceedings of the 7th International Conference on High Performance Computing and Networking, Europe. Lecture notes in computer science 1539. Berlin: Springer 1999: 430-9.
82. 14C-labelled 2-deoxyglucose autoradiograpby and histopathological examination. Nucl Med Commun 1995; 16: 443-6.
83. A-receptors. FASEB J 1990; 4: 1469-80.
84. Pasternak GW, Wood PJ. Multiple Mu opiate receptors. Life Sci 1986; 38: 1889-98.
85. Perlmutter JS, Kilbourn MR, Raichle ME et al. MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding in humans. Neurology 1987; 37: 1575-9.
86. Pfeiffer A, Pasi A, Mehraein P et al. Opiate receptor binding sites in human brain. Brain Res 1982; 248: 87-96.
87. Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997; 42: 720-6.
88. Piccini P, Burn DJ, Ceravolo R et al. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999; 45: 577-82.
89. 11C-Flumazenil positron emission tomography: An in vivo marker of neuronal loss in temporal lobe epilepsy. Epilepsia 1994; 35 (suppl 7): S 28.
90. Savage DD, Mills SA, Jobe PC et al. Elevation of naloxone-sensitive 3H-dihydromorphine binding in hippocampal formation of genetically epilepsy-prone rats. Life Sci 1988; 43: 239-46.
91. 11C)flumazenil positron emission tomography visualizes frontal epileptogenic regions. Epilepsia 1995; 36: 1225-32.
92. Schäfers KP. Imaging small animals with positron emission tomography. Nuklearmedizin 2003; 42: 86-9.
93. Siessmeier T, Heinz A, Wrase J et al. Craving is associated with D2-receptor binding in ventral striatum/nucleus accumbens. J Nucl Med 2002; 5 (suppl): 109p.
94. Smith YR, Zubieta JK, del Carmen MG et al. Brain opioid receptor measurements by positron emission tomography in normal cycling women: relationship to luteinizing hormone pulsatility and gonadal steroid hormones. J Clin Endocrinol Metab 1998; 83: 4498-505.
95. 11C methyl) naltrindole and positron emission tomography. J Cereb Blood Flow Metab 1999; 19: 956-66.
96. Sprenger T, Valet M, Boecker H et al. Heat pain triggers F-18 diprenophine displacement in the limbic system. J Cereb Blood Flow 2003; 23 (suppl 1): 719.
97. Stöcklin GL. Is there a future for clinical fluorine-18 radiopharmaceuticals (excluding FDG)? Eur J Nucl Med. 1998; 25: 1612-6.
98. Tatsch K. Imaging of the dopaminergic system in parkinsonism with SPECT. Nucl Med Commun 2001; 22: 819-27.
99. 18F)cyclofoxy. Epilepsy Res 1992; 13: 129-39.
100. Treede RD, Kenshalo DR, Gracely RH et al. The cortical representation of pain. Pain 1999; 79: 105-11.
101. Turjanski N, Weeks R, Dolan R et al. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 1995; 118: 689-99.
102. Uhl GR, Sora I, Wang Z. The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci USA 1999; 96: 7752-5.
103. Urca G, Frenk H, Liebesking et al. Morphine and enkephalin.analgesic and epileptic properties. Science 1977; 197: 83-6.
104. Verhoeff NP. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders. Psychopharmacology 1999; 147: 217-49.
105. 11C)raclopride in the human brain. Synapse 1994; 16: 255-62.
106. Wagner KJ, Willoch F, Kochs EF et al. Dose-dependent regional cerebral blood flow changes during remifentanil infusion in humans: a positron emission tomography study. Anesthesiology 2001; 94: 732-9.
107. Weckesser M, Schmidt D, Matheja P et al. The role of L-3-I-123-iodine-alpha-methyltyrosine SPECT in cerebral gliomas. Nuklearmedizin 2000; 39: 233-40.
108. 11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. J Cereb Blood Flow Metab. 1997; 17: 943-9.
109. Weinmann HJ, Ebert W, Misselwitz B et al. Tissue-specific MR contrast agents. Eur J Radiol 2003; 46: 33-44
110. Weiller C, May A, Limmroth V et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1: 658-60.
111. 11C)DPN in humans. J Nucl Med 2000; 41: 1279-86.
112. Willoch F, Schütz C, Wester HJ et al. Opioid receptor binding changes in alcohol dependent males during detoxification and in comparison to control. J Nucl Med 1999; 40: 111p.
113. Willoch F, Tölle TR, Wester HJ et al. Central pain following pontine infarction is associated with changes in opioid receptor binding: a PET study with C-11 diprenorphine. Am J Neuroradiol 1999; 20: 145-9.
114. Winkler PA., Herzog C, Henkel A et al. Nicht invasives Protokoll für die epilepsiechirurgische Behandlung fokaler Epilepsien. Nervenarzt 1999; 70: 1088-93.
115. Zartler ER, Yan J, Mo H et al. ID NMR Methods in ligand-receptor interactions. Curr Top Med Chem 2003; 3: 25-37.
116. Zeki S, Watson JD, Lueck CJ et al. A direct demonstration of functional specialization in human visual cortex. J Neurosci 1991; 11: 641-9.
117. Zieglgänsberger W, French ED, Siggins GR et al. Opioid peptides may excite hippocampal pyramidal neurons by inhibiting adjacent inhibitory interneurons. Science 1979; 205: 415-7.
118. Zubieta JK, Gorelick DA, Stauffer R et al. Increased mu opioid receptor binding detected by PET in cocaine-dependent man is associated with cocaine craving. Nature Med 1996; 2: 1225-9.
119. Zubieta JK, Dannals RF, Frost JJ. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry 1999; 156: 842-8.
120. Zubieta JK, Smith YR, Bueller JA et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 2001; 293: 311-5.
121. 11C) NMPB and PET. Synapse 2001; 39: 275-87.